Cargando…
Predictors of teriparatide treatment failure in patients with low bone mass
INTRODUCTION: While teriparatide is the only skeletal anabolic agent approved in the United States, treatment failure is a major concern which complicates its clinical utility. We sought to identify factors that predict response failure in patients with low bone mass. METHOD: We performed a retrospe...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926837/ https://www.ncbi.nlm.nih.gov/pubmed/28326338 http://dx.doi.org/10.1016/j.bonr.2015.11.001 |